Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Doses First Patients in Ziftomenib Combo Trial for Advanced GIST
Details : KO-539 (ziftomenib)is a potent and selective, oral investigational menin inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST) after imatinib failure.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2025
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura And Kyowa Submit NDA To FDA for Ziftomenib in Cancer Treatment
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura & Kyowa Kirin Announce Ziftomenib Monotherapy & FDA-Backed Frontline Trials
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2025
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Kyowa Kirin
Deal Size : $1,491.0 million
Deal Type : Collaboration
Kura Oncology to Partner with Kyowa Kirin for Blood Cancer Therapy
Details : The collaboration aims to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with AML and other hematologic malignancies.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : $330.0 million
November 20, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Kyowa Kirin
Deal Size : $1,491.0 million
Deal Type : Collaboration
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Preclinical Data Supports Ziftomenib for Gastrointestinal Tumors
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Oncology Receives FDA IND Clearance For Menin Inhibitor Ziftomenib in GIST
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated in combination with imatinib for the treatment of patients with advanced gastrointestinal stromal tumors.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2024
Lead Product(s) : Ziftomenib,Imatinib Mesylate
Therapeutic Area : Gastroenterology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Oncology Completes Enrollment in Reg-Directed Trial of Ziftomenib in NPM1-Mutant AML
Details : KO-539 (ziftomenib), a menin-KMT2A/MLL inhibitor, being investigated for the treatment of patients with relapsed/refractory NPM1-mutant acute myeloid leukemia (AML).
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Details : KO-539 (ziftomenib) is a menin-KMT2A/MLL inhibitor that has received Breakthrough Therapy Designation from the FDA for treating relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Gilteritinib Fumarate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Doses First Patient in KOMET-008 Trial of Ziftomenib with Standards of Care in AML
Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 1 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Ziftomenib,Fludarabine Phosphate,Gilteritinib Fumarate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kura Reports Positive Preliminary Ziftomenib Combination Data in AML
Details : KO-539 (ziftomenib) is a potent and selective a menin-MLL(KMT2A) inhibitor, which is being evaluated in phase 2 clinical trials in patients with NPM1-mutant & KMT2A-rearranged acute myeloid leukemia.
Product Name : KO-539
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2024
Lead Product(s) : Ziftomenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable